Anwen Xiong

机构：Tongji University, Shanghai Pulmonary Hospital, Shanghai East Hospital

发表论文 64 篇 · 总被引 2082 次 · h-index 20

代表论文

• Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China (2025 · The Lancet · 被引 154)
• A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC (2023 · Journal of Thoracic Oncology · 被引 63)
• Taletrectinib in ROS1 + Non–Small Cell Lung Cancer: TRUST (2025 · Journal of Clinical Oncology · 被引 55)
• Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non–Small Cell Lung Cancer: The Phase II TRUST-I Study (2024 · Journal of Clinical Oncology · 被引 36)
• CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer (2024 · Signal Transduction and Targeted Therapy · 被引 17)
• Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study (2024 · Journal of Hematology & Oncology · 被引 14)